NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF

Title:

NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2022/065894

Kind Code:

A1

Abstract:

The present invention relates to a novel quinazoline derivative having fms-like tyrosine kinase 3 (FLT3) inhibitory activity, and use thereof. A novel benzoimidazole derivative or a pharmaceutically-acceptable salt thereof, according to the present invention, exhibits excellent inhibitory activity with respect to FLT3, and thus targeted treatment through more fundamental approaches is expected in the prevention or treatment of acute myeloid leukemia (AML).

More Like This:

JPS6239583	BENZODIOXAZOLE DERIVATIVE AND PRODUCTION THEREOF
JPH11246437	GASTROINTESTINAL MUCOSA PROTECTING AGENT
WO/2006/002236	N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER

Inventors:

HAH JUNG-MI (KR)
IM DA SEUL (KR)

Application Number:

PCT/KR2021/012997

Publication Date:

March 31, 2022

Filing Date:

September 24, 2021

Export Citation:

Click for automatic bibliography generation Help

Assignee:

IUCF HYU ERICA CAMPUS (KR)

International Classes:

C07D413/12; A61K31/506; A61K31/517; A61K31/5377; A61P35/00; A61P35/02; C07D413/14

Domestic Patent References:

WO2004030671A2

2004-04-15

Foreign References:

KR102085692B1	2020-03-06
US20160194291A1	2016-07-07
US20080207617A1	2008-08-28

Other References:

IM D.: "Discovery of 5-methyl-N-(2-arylquinazolin-7-yl)isoxazole-4-carboxamide analogues as highly selective FLT3 inhibitors", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 35, no. 1, 1 January 2020 (2020-01-01), pages 1110 - 1115, XP055914737

Attorney, Agent or Firm:

DANA PATENT LAW FIRM (KR)

Download PDF:

View/Download PDF PDF Help

Previous Patent: MEDIA FILE PROCESSING METHOD AND DEVICE THEREFOR

Next Patent: NOVEL SALT OF EMPAGLIFLOZIN DERIVATIVE, WHICH IS SGLT-2 INHIBITOR, AND HYDRATE OF SALT